Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cybin has acquired Phase 1 N,N-DMT study
  • DMT study expected to accelerate the clinical development path of CYB004
  • Multiple clinical-stage programs are currently ongoing
  • Cybin’s proprietary deuterated DMT molecule designed for the potential treatment of anxiety disorders
  • Cybin Inc. is down 6.41 per cent trading at $0.73 per share at close-of-day trading at 4 pm EDT.

Cybin (CYBN) has completed the acquisition of a Phase 1 N, N-dimethyltryptamine (DMT) study from Entheon Biomedical Corp. (CSE:ENBI).

This DMT study, its largest to date, is expected to accelerate the clinical development path of CYB004 – Cybin’s proprietary deuterated DMT molecule for the potential treatment of anxiety disorders, by approximately nine months.

Primary objectives:

  • Evaluate the safety of increasing doses of a single dose continuous DMT infusion over 90 minutes
  • Characterize the PK of a single dose DMT administered continuously over 90 minutes
  • Characterize the PD of a single dose DMT administered continuously over 90 minutes
  • And, establish the minimum DMT dose required to produce a psychedelic effect.

Doug Drysdale, CEO of Cybin, commented on the transaction.

“With the closing of this transaction, we are well on our way to advancing CYB004 through Phase 1 development and gathering essential safety and dosing optimization data that will inform the clinical path forward for this important molecule. Cybin now has multiple clinical-stage programs ongoing that we believe will contribute significantly to a greater understanding of the potential of psychedelics to provide therapeutic relief to patients who suffer with a variety of mental health issues.”

Cybin Inc. is down 6.41 per cent trading at $0.73 per share at close-of-day trading at 4 pm EDT.

More From The Market Herald

" The Market Herald’s Weekly Cannabis Report. August 12, 2022

Aleafia Health (TSX:AH) earns record quarter-over-quarter revenue in Q1 2023

" The Market Herald’s Weekly Cannabis Report. August 5, 2022.

1 | Top Story: High Tide Inc. (TSXV:HITI) acquires retail stores in B.C. and Alberta
Field Trip Health - CEO, Joseph del Moral.

" Field Trip (TSX:FTRP) receives conditional approval to list common shares of Field Trip Health & Wellness on the TSXV

The TSX Venture Exchange (TSXV) has issued conditional listing approval to Field Trip Health Limited (FTRP).

" Optimind Pharma (CSE:OMND) commences trading on the CSE

Optimind Pharma (OMND) will begin trading on the CSE under the ticker symbol OMND.